7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Carcinoma D002277 18 associated lipids
Carcinoma, Non-Small-Cell Lung D002289 72 associated lipids
Carcinoma, Papillary D002291 3 associated lipids
Carcinosarcoma D002296 7 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Celiac Disease D002446 16 associated lipids
Brain Ischemia D002545 89 associated lipids
Cherubism D002636 1 associated lipids
Chondroblastoma D002804 1 associated lipids
Chondrocalcinosis D002805 1 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Younes A and Aggarwall BB Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. 2003 Cancer pmid:12879461
Liu JZ et al. [Expression of human osteoprotegerin gene in E. Coli and bioactivity analysis of expression product]. 2003 Zhonghua Wai Ke Za Zhi pmid:14680558
Nawroth P et al. [Osteoporosis and cardiovascular disease--two sides of the same coin?]. 2003 Med. Klin. (Munich) pmid:12928809
Nakatsuka K et al. Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. 2003 J. Bone Miner. Res. pmid:12929927
Li JP and Ling JQ [Tumor necrosis factor and lipopolysaccharide affect periodontal ligament cells expressing osteoprotegerin in vitro]. 2003 Zhonghua Kou Qiang Yi Xue Za Zhi pmid:12930661
Schett G et al. The role of osteoprotegerin in arthritis. 2003 Arthritis Res. Ther. pmid:12932284
Gehrke T et al. Receptor activator of nuclear factor kappaB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening. 2003 Scand. J. Rheumatol. pmid:14690142
Stolina M et al. Regulatory effects of osteoprotegerin on cellular and humoral immune responses. 2003 Clin. Immunol. pmid:14697750
Kapczuk K et al. [Osteoprotegerin/RANKL/RANK system and postmenopausal osteoporosis. The possible therapeutic aspects]. 2003 Ginekol. Pol. pmid:12916277
Liu JZ et al. [Co-expression of human bone morphogenetic protein-2 and osteoprotegerin in myoblast C2C12]. 2003 Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi pmid:12916296
Bendre MS et al. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. 2003 Bone pmid:12919697
Tabb MM et al. Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. 2003 J. Biol. Chem. pmid:12920130
Park HR et al. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. 2003 J. Korean Med. Sci. pmid:12923331
Naylor KE et al. Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation. 2003 J. Clin. Endocrinol. Metab. pmid:14602774
Paloneva J et al. DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. 2003 J. Exp. Med. pmid:12925681
Fukushima H et al. Expression and role of RANKL in periodontal ligament cells during physiological root-resorption in human deciduous teeth. 2003 Eur. J. Oral Sci. pmid:12887401
Ito R et al. Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. 2003 Virchows Arch. pmid:12838418
Hayashi S et al. Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha. 2003 J. Immunol. pmid:14607912
Terpos E et al. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. 2003 Int. J. Cancer pmid:12845688
Padigel UM et al. TRANCE-RANK costimulation is required for IL-12 production and the initiation of a Th1-type response to Leishmania major infection in CD40L-deficient mice. 2003 J. Immunol. pmid:14607948
Schett G et al. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. 2003 Arthritis Rheum. pmid:12847699
Gruber HE and Rude RK Alterations in osteoclast morphology following osteoprotegerin administration in the magnesium-deficient mouse. 2003 Biotech Histochem pmid:14989640
Wagner TU et al. The teleost fish medaka (Oryzias latipes) as genetic model to study gravity dependent bone homeostasis in vivo. 2003 Adv Space Res pmid:15000082
Terpos E et al. New insights into the pathophysiology and management of bone disease in multiple myeloma. 2003 Br. J. Haematol. pmid:14632767
Ha H et al. Lipid rafts are important for the association of RANK and TRAF6. 2003 Exp. Mol. Med. pmid:14508068
Zhang L et al. The role of calmodulin in the regulation of osteoclastogenesis. 2003 Endocrinology pmid:12960067
Miyahira Y et al. Cutting edge: a potent adjuvant effect of ligand to receptor activator of NF-kappa B gene for inducing antigen-specific CD8+ T cell response by DNA and viral vector vaccination. 2003 J. Immunol. pmid:14662831
Seidlova-Wuttke D et al. Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. 2003 Eur. J. Endocrinol. pmid:14514351
Hortobagyi GN Novel approaches to the management of bone metastases. 2003 Semin. Oncol. pmid:14613037
Voskaridou E et al. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. 2003 Br. J. Haematol. pmid:14616979
Uemura H et al. Circulating osteoprotegerin in women during GnRH-agonist treatment and their relationships with mineral components and biomarkers of bone turnover. 2003 Bone pmid:14623063
Novack DV TSH, the bone suppressing hormone. 2003 Cell pmid:14567908
Abe E et al. TSH is a negative regulator of skeletal remodeling. 2003 Cell pmid:14567913
Zhao ZM et al. [The preliminary study on in vitro differentiation of human umbilical cord blood cells into neural cells]. 2003 Zhonghua Xue Ye Xue Za Zhi pmid:14575594
Boyan BD et al. Osteoblasts generate an osteogenic microenvironment when grown on surfaces with rough microtopographies. 2003 Eur Cell Mater pmid:14577052
Zhang J et al. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. 2003 Cancer Res. pmid:14633717
Chan BY et al. Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. 2003 Clin. Chem. pmid:14633883
Jung K et al. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. 2003 J. Urol. pmid:14634401
Su X et al. [The effects of 17 beta-estradiol on the expression of osteoprotegerin, the ligand of osteoprotegerin and related cytokines in osteosarcoma MG63 cells]. 2003 Zhonghua Nei Ke Za Zhi pmid:14636471
Takayanagi H [Crosstalk between the immune and skeletal system]. 2003 Ryumachi pmid:14598653
Cho TJ et al. Tumor necrosis factor alpha activation of the apoptotic cascade in murine articular chondrocytes is associated with the induction of metalloproteinases and specific pro-resorptive factors. 2003 Arthritis Rheum. pmid:14558090
Koshihara Y et al. Vitamin K stimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture. 2003 J. Endocrinol. pmid:12630919
Alvarez L et al. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. 2003 Arthritis Rheum. pmid:12632438
Bord S et al. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. 2003 Bone pmid:12633785
Garber K Why it hurts: researchers seek mechanisms of cancer pain. 2003 J. Natl. Cancer Inst. pmid:12783923
Chagraoui H et al. Expression of osteoprotegerin mRNA and protein in murine megakaryocytes. 2003 Exp. Hematol. pmid:14585373
Liu B et al. Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts. 2003 J. Oral Pathol. Med. pmid:12787044
Eaton CL and Coleman RE Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. 2003 Cancer Treat. Rev. pmid:12787713
Fahrleitner-Pammer A et al. Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. 2003 Wien. Klin. Wochenschr. pmid:12793029
Dovio A et al. Correspondence re: A. Lipton et al., Serum osteoprotegerin levels in healthy controls and cancer patients. Clin. Cancer Res., 8: 2306-2310, 2002. 2003 Clin. Cancer Res. pmid:12796409
Flick LM et al. Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. 2003 J. Orthop. Res. pmid:12798068
Khapli SM et al. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage. 2003 J. Immunol. pmid:12816992
Kawase Y et al. Bone malformations in interleukin-18 transgenic mice. 2003 J. Bone Miner. Res. pmid:12817749
Kikuchi T et al. Cot/Tpl2 is essential for RANKL induction by lipid A in osteoblasts. 2003 J. Dent. Res. pmid:12821717
D'Elia HF et al. Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1. 2003 Arthritis Res. Ther. pmid:12823855
Knudsen ST et al. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. 2003 Eur. J. Endocrinol. pmid:12824864
Fox SW et al. The possible role of TGF-beta-induced suppressors of cytokine signaling expression in osteoclast/macrophage lineage commitment in vitro. 2003 J. Immunol. pmid:12646633
Varsani H et al. Synovial dendritic cells in juvenile idiopathic arthritis (JIA) express receptor activator of NF-kappaB (RANK). 2003 Rheumatology (Oxford) pmid:12649407
Cheung J et al. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. 2003 J. Endocrinol. pmid:12773123
Nakamura H et al. Suppression of osteoblastic phenotypes and modulation of pro- and anti-apoptotic features in normal human osteoblastic cells under a vector-averaged gravity condition. 2003 J. Med. Dent. Sci. pmid:12968638
Viereck V et al. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. 2003 J. Clin. Endocrinol. Metab. pmid:12970288
Okada Y et al. Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone. 2003 J. Biol. Chem. pmid:12665515
Bell NH RANK ligand and the regulation of skeletal remodeling. 2003 J. Clin. Invest. pmid:12697730
Eghbali-Fatourechi G et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. 2003 J. Clin. Invest. pmid:12697741
Enomoto H et al. Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene. 2003 J. Biol. Chem. pmid:12697767
Nakashima T et al. RANKL and RANK as novel therapeutic targets for arthritis. 2003 Curr Opin Rheumatol pmid:12707582
Johnson-Pais TL et al. Determination of a minimal region of loss of heterozygosity on chromosome 18q21.33 in osteosarcoma. 2003 Int. J. Cancer pmid:12673693
Zaidi M et al. Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. 2003 J. Bone Miner. Res. pmid:12674320
Tanaka S et al. Signal transduction pathways regulating osteoclast differentiation and function. 2003 J. Bone Miner. Metab. pmid:12720046
Valleala H et al. Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. 2003 Eur. J. Endocrinol. pmid:12720535
Yonou H et al. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. 2003 Cancer Res. pmid:12727825
Capparelli C et al. Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. 2003 J. Bone Miner. Res. pmid:12733724
Wong T et al. Therapeutic implications for interferon-alpha in arthritis: a pilot study. 2003 J. Rheumatol. pmid:12734885
Al-Qawasmi RA et al. Genetic predisposition to external apical root resorption in orthodontic patients: linkage of chromosome-18 marker. 2003 J. Dent. Res. pmid:12709501
Fujita D et al. Prostaglandin E2 induced the differentiation of osteoclasts in mouse osteoblast-depleted bone marrow cells. 2003 Prostaglandins Leukot. Essent. Fatty Acids pmid:12711253
Katavić V et al. Increased bone mass is a part of the generalized lymphoproliferative disorder phenotype in the mouse. 2003 J. Immunol. pmid:12538719
Clohisy D Cellular mechanisms of osteolysis. 2003 J Bone Joint Surg Am pmid:12540662
Vanderkerken K et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. 2003 Cancer Res. pmid:12543775
Yu Q et al. Cooperation of TNF family members CD40 ligand, receptor activator of NF-kappa B ligand, and TNF-alpha in the activation of dendritic cells and the expansion of viral specific CD8+ T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals. 2003 J. Immunol. pmid:12574344
Xing L et al. Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. 2003 J. Bone Miner. Res. pmid:12568403
Cao J et al. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. 2003 J. Bone Miner. Res. pmid:12568404
Johnson-Pais TL et al. Identification of a novel tandem duplication in exon 1 of the TNFRSF11A gene in two unrelated patients with familial expansile osteolysis. 2003 J. Bone Miner. Res. pmid:12568416
Clohisy JC et al. RANKL is an essential cytokine mediator of polymethylmethacrylate particle-induced osteoclastogenesis. 2003 J. Orthop. Res. pmid:12568950
Fahrleitner A et al. Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. 2003 Bone pmid:12584041
Lanzi R et al. GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults. 2003 Eur. J. Endocrinol. pmid:12590637
Shipman CM and Croucher PI Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. 2003 Cancer Res. pmid:12615702
Hamzei M et al. Osteoclast stimulating and differentiating factors in human cholesteatoma. 2003 Laryngoscope pmid:12616193
Siggelkow H et al. Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases. 2003 J. Bone Miner. Res. pmid:12619938
Toraldo G et al. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. 2003 Proc. Natl. Acad. Sci. U.S.A. pmid:12490655
Nishimura K et al. Effects of irradiation on cementum matrix cytokins function during periodontal regeneration. 2003 Hum. Cell pmid:15147042
Choi BK et al. Induction of osteoclastogenesis and matrix metalloproteinase expression by the lipooligosaccharide of Treponema denticola. 2003 Infect. Immun. pmid:12496170
Liu D et al. Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction. 2003 Int. J. Mol. Med. pmid:12469211
Rude RK et al. Magnesium deficiency: effect on bone and mineral metabolism in the mouse. 2003 Calcif. Tissue Int. pmid:12370796
Takayanagi H [Signaling mechanism in the regulation of osteoclast differentiation by the immune system]. 2003 Seikagaku pmid:14748148
Chen X et al. Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. 2003 J. Nutr. Biochem. pmid:12873716
Bridgham JT and Johnson AL Characterization of chicken TNFR superfamily decoy receptors, DcR3 and osteoprotegerin. 2003 Biochem. Biophys. Res. Commun. pmid:12878204
Riggs BL et al. Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency. 2003 Osteoporos Int pmid:12879223
Crotti TN et al. Variability of RANKL and osteoprotegerin staining in synovial tissue from patients with active rheumatoid arthritis: quantification using color video image analysis. 2003 J. Rheumatol. pmid:14677171
Sasaki T Differentiation and functions of osteoclasts and odontoclasts in mineralized tissue resorption. 2003 Microsc. Res. Tech. pmid:12879416
Helfrich MH Osteoclast diseases. 2003 Microsc. Res. Tech. pmid:12879419

Table of Content